The aging myostatin null phenotype: Reduced adiposity, cardiac hypertrophy, enhanced cardiac stress response, and sexual dimorphism

Journal of Endocrinology

Volumn 213, Issue 3, 2012, Pages 263-275

  Jackson, Melissa F ^a   Luong, Dung ^a   Vang, Dor Dor ^b   Garikipati, Dilip K ^b   Stanton, James B ^a   Nelson, O Lynne ^a   Rodgers, Buel D ^a,b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Animal Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPRENALINE; MYOSTATIN;

ADIPOCYTE; AGED; AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BROWN ADIPOSE TISSUE; CARDIOVASCULAR RISK; CELL SIZE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART HYPERTROPHY; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE; HEART PERFORMANCE; HEART STRESS; KIDNEY; LEAN BODY WEIGHT; MALE; MOUSE; MUSCLE MASS; NONHUMAN; NULL ALLELE; OBESITY; PHARMACOLOGIC STRESS TESTING; PHENOTYPE; PRIORITY JOURNAL; SEX DIFFERENCE; SKELETAL MUSCLE; SPLEEN; WHITE ADIPOSE TISSUE; WILD TYPE;

ADIPOSE TISSUE, BROWN; ADIPOSITY; AGING; ANIMALS; BONE DENSITY; CARDIOMEGALY; CARDIOTONIC AGENTS; FEMALE; HEART FUNCTION TESTS; HEART RATE; ISOPROTERENOL; KIDNEY; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SKELETAL; MYOCARDIUM; MYOSTATIN; ORGAN SIZE; PHENOTYPE; REGRESSION ANALYSIS; SEX FACTORS; SPLEEN; TIME FACTORS;

EID: 84864292994     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-11-0455     Document Type: Article

References (57)

1. Abergel E, Chatellier G, Hagege AA, Oblak A, Linhart A, Ducardonnet A & Menard J 2004 Serial left ventricular adaptations in world-class professional cyclists: implications for disease screening and follow-up. Journal of the American College of Cardiology 44 144-149.
2. Artaza JN, Reisz-Porszasz S, Dow JS, Kloner RA, Tsao J, Bhasin S & Gonzalez-Cadavid NF 2007 Alterations in myostatin expression are associated with changes in cardiac left ventricular mass but not ejection fraction in the mouse. Journal of Endocrinology 194 63-76.
3. Bavegems V, Van Caelenberg A, Duchateau L, Sys SU, Van Bree H & De Rick A 2005 Vertebral heart size ranges specific for whippets. Veterinary Radiology & Ultrasound 46 400-403.
4. Bavegems V, Duchateau L, Sys SU & De Rick A 2007 Echocardiographic reference values in whippets. Veterinary Radiology & Ultrasound 48 230-238.
5. Bish LT, Morine KJ, Sleeper MM & Sweeney HL 2010 Myostatin is upregulated following stress in an Erk-dependent manner and negatively regulates cardiomyocyte growth in culture and in a mouse model. PLoS ONE 5 e10230.
6. Bogdanovich S, Perkins KJ, Krag TO, Whittemore LA & Khurana TS 2005 Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB Journal 19 543-549.
7. Catalucci D, Latronico MV, Ellingsen O & Condorelli G 2008 Physiological myocardial hypertrophy: how and why? Frontiers in Bioscience 13 312-324
8. Choi SJ, Yablonka-Reuveni Z, Kaiyala KJ, Ogimoto K, Schwartz MW & Wisse BE 2011 Increased energy expenditure and leptin sensitivity account for low fat mass in myostatin deficient mice. American Journal of Physiology. Endocrinology and Metabolism 300 E1031-E1037.
9. Cohn RD, Liang HY, Shetty R, Abraham T & Wagner KR 2007 Myostatin does not regulate cardiac hypertrophy or fibrosis. Neuromuscular Disorders 17 290-296.
10. Colan SD 1992 Mechanics of left ventricular systolic and diastolic function in physiologic hypertrophy of the athlete heart. Cardiology Clinics 10 227-240.
11. Cook SA, Matsui T, Li L & Rosenzweig A 2002 Transcriptional effects of chronic Akt activation in the heart. Journal of Biological Chemistry 277 22528-22533.
12. Cruz-Jentoft AJ, Landi F, Topinkova E & Michel JP 2010 Understanding sarcopenia as a geriatric syndrome. Current Opinion in Clinical Nutrition and Metabolic Care 13 1-7.
13. Dilger AC, Spurlock ME, Grant AL & Gerrard DE 2010 Myostatin null mice respond differently to dietary-induced and genetic obesity. Animal Science Journal 81 586-593.
14. Gaussin V & Depre C 2005 Myostatin, the cardiac chalone of insulin-like growth factor-1. Cardiovascular Research 68 347-349.
15. George I, Bish LT, Kamalakkannan G, Petrilli CM, Oz MC, Naka Y, Sweeney HL & Maybaum S 2010 Myostatin activation in patients with advanced heart failure and after mechanical unloading. European Journal of Heart Failure 12 444-453.
16. Guo T, Jou W, Chanturiya T, Portas J, Gavrilova O & McPherron AC 2009 Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivity. PLoS ONE 4 e4937.
17. Hamrick MW 2003 Increased bone mineral density in the femora of GDF8 knockout mice. Anatomical Record 272A 388-391.
18. Hamrick MW, McPherron AC & Lovejoy CO 2002 Bone mineral content and density in the humerus of adult myostatin- deficient mice. Calcified Tissue International 13 13.
19. Hamrick MW, Pennington C & Byron CD 2003 Bone architecture and disc degeneration in the lumbar spine of mice lacking GDF-8 (myostatin). Journal of Orthopaedic Research 21 1025-1032.
20. Heineke J, Auger-Messier M, Xu J, Sargent M, York A, Welle S & Molkentin JD 2010 Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation 121 419-425.
21. Helterline DL, Garikipati D, Stenkamp DL & Rodgers BD 2007 Embryonic and tissue-specific regulation of myostatin-1 and -2 gene expression in zebrafish. General and Comparative Endocrinology 151 90-97.
22. Kellum E, Starr H, Arounleut P, Immel D, Fulzele S, Wenger K & HamrickMW 2009 Myostatin (GDF-8) deficiency increases fracture callus size, Sox-5 expression, and callus bone volume. Bone 44 17-23.
23. Khurana TS & Davies KE 2003 Pharmacological strategies for muscular dystrophy. Nature Reviews. Drug Discovery 2 379-390.
24. Lang T, Streeper T, Cawthon P, Baldwin K, Taaffe DR & Harris TB 2010 Sarcopenia: etiology, clinical consequences, intervention, and assessment. Osteoporosis International 21 543-559.
25. Lebrasseur NK, Schelhorn TM, Bernardo BL, Cosgrove PG, Loria PM & Brown TA 2009 Myostatin inhibition enhances the effects of exercise on performance and metabolic outcomes in aged mice inhibition enhances the effects of exercise on performance and metabolic outcomes in aged mice. Journal of Gerontology: Biological Sciences 64A 940-948.
26. Lin J, Arnold HB, Della-Fera MA, Azain MJ, Hartzell DL & Baile CA 2002 Myostatin knockout in mice increases myogenesis and decreases adipogenesis. Biochemical and Biophysical Research Communications 291 701-706.
27. Lonsdale RA, Labuc RH & Robertson ID 1998 Echocardiographic parameters in training compared with non-training greyhounds. Veterinary Radiology & Ultrasound 39 325-330.
28. Matsakas A, Foster K, Otto A, Macharia R, Elashry MI, Feist S, Graham I, Foster H, Yaworsky P, Walsh F et al. 2009 Molecular, cellular and physiological investigation of myostatin propeptide-mediated muscle growth in adult mice. Neuromuscular Disorders 19 489-499.
29. McKoy G, Bicknell KA, Patel K & Brooks G 2007 Developmental expression of myostatin in cardiomyocytes and its effect on foetal and neonatal rat cardiomyocyte proliferation. Cardiovascular Research 74 304-312.
30. McMullen JR & Jennings GL 2007 Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure. Clinical and Experimental Pharmacology & Physiology 34 255-262.
31. McPherron AC & Lee SJ 2002 Suppression of body fat accumulation in myostatin-deficient mice. Journal of Clinical Investigation 109 595-601.
32. Morissette MR, Cook SA, Foo S, McKoy G, Ashida N, Novikov M, Scherrer-Crosbie M, Li L, Matsui T, Brooks G et al. 2006 Myostatin regulates cardiomyocyte growth through modulation of Akt signaling. Circulation Research 99 15-24.
33. Morissette MR, Stricker JC, Rosenberg MA, Buranasombati C, Levitan EB, Mittleman MA & Rosenzweig A 2009 Effects of myostatin deletion in aging mice. Aging Cell 8 573-583.
34. Ohlsson C, Mohan S, Sjogren K, Tivesten A, Isgaard J, Isaksson O, Jansson JO & Svensson J 2009 The role of liver-derived insulin-like growth factor-I. Endocrine Reviews 30 494-535.
35. Pape LA, Rippe JM, Walker WS, Weiner BH, Ockene IS, Paraskos JA, Alpert JS, Kotilainin P & Matthews M 1984 Effects of the cessation of training on left-ventricular function in the racing greyhound - serial studies in a model of cardiac-hypertrophy. Basic Research in Cardiology 79 98-109.
36. Pavlik G, Bachl N, Wollein W, Langfy G & Prokop L 1986 Resting echocardiographic parameters after cessation of regular endurance training. International Journal of Sports Medicine 7 226-231.
37. Rippe JM, Pape LA, Alpert JS, Ockene IS, Paraskos JA, Kotilainen P, Anas J & WebsterW 1982 Studies of systolic mechanics and diastolic behavior of the left-ventricle in the trained racing greyhound. Basic Research in Cardiology 77 619-644.
38. Rodgers BD & Garikipati DK 2008 Clinical, agricultural, and evolutionary biology of myostatin: a comparative review. Endocrine Reviews 29 513-534.
39. Rodgers BD, Interlichia JP, Garikipati DK, Mamidi R, Chandra M, Nelson OL, Murry CE & Santana LF 2009 Myostatin represses physiological hypertrophy of the heart and excitation-contraction coupling. Journal of Physiology 587 4873-4886.
40. Saghir M, Areces M & Makan M 2007 Strain rate imaging differentiates hypertensive cardiac hypertrophy from physiologic cardiac hypertrophy (athlete's heart). Journal of the American Society of Echocardiography 20 151-157.
41. Schaible TF, Malhotra A, Ciambrone GJ & Scheuer J 1986 Chronic swimming reverses cardiac dysfunction and myosin abnormalities in hypertensive rats. Journal of Applied Physiology 60 1435-1441.
42. Sharma M, Kambadur R, Matthews KG, SomersWG, Devlin GP, Conaglen JV, Fowke PJ & Bass JJ 1999 Myostatin, a transforming growth factor-beta superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct. Journal of Cellular Physiology 180 1-9.
43. Shyu KG, Ko WH, Yang WS, Wang BW & Kuan P 2005 Insulin-like growth factor-1 mediates stretch-induced upregulation of myostatin expression in neonatal rat cardiomyocytes. Cardiovascular Research 68 405-414.
44. Shyu KG, Lu MJ, Wang BW, Sun HY & Chang H 2006 Myostatin expression in ventricular myocardium in a rat model of volume-overload heart failure. European Journal of Clinical Investigation 36 713-719.
45. Siriett V, Platt L, Salerno MS, Ling N, Kambadur R & Sharma M 2006 Prolonged absence of myostatin reduces sarcopenia. Journal of Cellular Physiology 209 866-873.
46. Siriett V, Salerno MS, Berry C, Nicholas G, Bower R, Kambadur R & Sharma M 2007 Antagonism of myostatin enhances muscle regeneration during sarcopenia. Molecular Therapy 15 1463-1470.
47. Snyder PS, Sato T & Atkins CE 1995 A comparison of echocardiographic indexes of the nonracing, healthy greyhound to reference values from other breeds. Veterinary Radiology & Ultrasound 36 387-392.
48. Stepien RL, Hinchcliff KW, Constable PD & Olson J 1998 Effect of endurance training on cardiac morphology in Alaskan sled dogs. Journal of Applied Physiology 85 1368-1375.
49. Valdivia HH 2009 Take it to heart: myostatin inhibition, mighty mouse and the quest for a competitive edge. Journal of Physiology 587 5005.
50. Wagner KR, Liu X, Chang X & Allen RE 2005 Muscle regeneration in the prolonged absence of myostatin. PNAS 102 2519-2524.
51. Whyte G, Lumley S, GeorgeK, GatesP, Sharma S, Prasad K, & McKenna WJ 2000 Physiological profile and predictors of cycling performance in ultra-endurance triathletes. Journal of Sports Medicine and Physical Fitness 40 103-109.
52. Wilkes JJ, Lloyd DJ & Gekakis N 2009 Loss-of-function mutation in myostatin reduces tumor necrosis factor alpha production and protects liver against obesity-induced insulin resistance. Diabetes 58 1133-1143.
53. Williams NG, Interlichia JP, Jackson MF, Hwang D, Cohen P & Rodgers BD 2011 Endocrine actions of myostatin: systemic regulation of the IGF and IGF binding protein axis. Endocrinology 152 172-180.
54. Winett RA, Williams DM & Davy BM 2009 Initiating and maintaining resistance training in older adults: a social cognitive theory-based approach. British Journal of SportsMedicine 43 114-119.
55. Yablonka-Reuveni Z 2007 Myostatin blockade: a new way to enhance skeletal muscle repair in old age? Molecular Therapy 15 1407-1409
56. Yin FC, Spurgeon HA, Rakusan K, Weisfeldt ML & Lakatta EG 1982 Use of tibial length to quantify cardiac hypertrophy: application in the aging rat. American Journal of Physiology 243 H941-H947.
57. Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, Rosenfeld R, Chen Q, Boone T, Simonet WS et al. 2010 Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142 531-543.